VEGF-A在子宫内膜异位症中的研究进展

子宫内膜异位症（EMs）是育龄妇女的多发病，主要引起盆腔疼痛及不孕，近几年发病率有明显上升趋势。如同肿瘤的生长及复发，异位EMs病灶周围的血管化程度是影响子宫内膜细胞增殖、转移和EMs病灶复发的重要因素，因此抑制血管内皮生长因子A（VEGF-A）成为了EMs治疗的新目标。近年来对VEGF-A在EMs中作用的相关研究，如VEGF-A作为EMs的诊断标志物、VEGF-A基因多态性、VEGF-A抑制剂用于EMs的治疗以及微小RNA（miRNA）对VEGF的表达调控等都取得了一定的进展，有助于进一步揭示EMs的发病、病灶转移以及复发的机制，以便更准确地评估EMs病情的进展及复发。现综述近年来VEGF-A在EMs中的研究进展。

The Research Progress of VEGF-A in Endometriosis

Endometriosis (EMs) is a frequent occurrence of women with reproductive age, which mainly causes pain and infertility. As tumor growth and recurrence of ectopic EMs around the lesion vascularization degree of endothelial cell proliferation, metastasis and recurrence of EMs lesions of important factors, so the inhibition of vascular endothelial growth factor has become the new target of EMs treatment. Recent studies on the role of VEGF-A in EMs, such as VEGF, as a diagnostic marker of EMs, VEGF-A gene polymorphism, VEGF-A receptor inhibitor for the treatment of EMs and microRNA (miRNA) expression of VEGF in regulating, have made certain progress, help to further reveal the onset of EMs, recurrent focal shift and focal mechanisms, as well as more accurately assess the EMs of progression and recurrence. Recent advances in the research of VEGF-A in EMs are reviewed.